Recurrence-free and overall survival in ER-positive patients by Cox univariate analysis
Category . | n . | Recurrence-free survival . | . | Overall survival . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | RR (95% CI) . | P . | RR (95% CI) . | P . | |||||
Cyclin D1 nf <25% | ||||||||||
Control | 83 | 1.00 | 1.00 | |||||||
Tamoxifen | 56 | 0.62 (0.37-1.04) | 0.07 | 0.65 (0.37-1.14) | 0.14 | |||||
Cyclin D1 nf >25% | ||||||||||
Control | 84 | 1.00 | 1.00 | |||||||
Tamoxifen | 88 | 0.61 (0.38-0.96) | 0.03 | 0.78 (0.48-1.25) | 0.30 | |||||
Cyclin D1 ni low/intermediate | ||||||||||
Control | 149 | 1.00 | 1.00 | |||||||
Tamoxifen | 120 | 0.59 (0.41-0.85) | 0.004 | 0.72 (0.50-1.06) | 0.10 | |||||
Cyclin D1 ni high | ||||||||||
Control | 18 | 1.00 | 1.00 | |||||||
Tamoxifen | 24 | 0.84 (0.30-2.31) | 0.73 | 0.77 (0.27-2.19) | 0.62 | |||||
Cyclin A2 nf <10% | ||||||||||
Control | 90 | 1.00 | 1.00 | |||||||
Tamoxifen | 69 | 0.51 (0.30-0.86) | 0.01 | 0.72 (0.42-1.25) | 0.25 | |||||
Cyclin A2 nf >10% | ||||||||||
Control | 52 | 1.00 | 1.00 | |||||||
Tamoxifen | 51 | 0.86 (0.50-1.47) | 0.59 | 0.92 (0.53-1.59) | 0.75 | |||||
CCND1 not amplified | ||||||||||
Control | 79 | 1.00 | 1.00 | |||||||
Tamoxifen | 72 | 0.39 (0.23-0.65) | <0.0001 | 0.43 (0.24-0.76) | 0.004 | |||||
CCND1 amplified | ||||||||||
Control | 21 | 1.00 | 1.00 | |||||||
Tamoxifen | 21 | 2.22 (0.94-5.26) | 0.06 | 2.13 (0.89-5.10) | 0.09 |
Category . | n . | Recurrence-free survival . | . | Overall survival . | . | |||||
---|---|---|---|---|---|---|---|---|---|---|
. | . | RR (95% CI) . | P . | RR (95% CI) . | P . | |||||
Cyclin D1 nf <25% | ||||||||||
Control | 83 | 1.00 | 1.00 | |||||||
Tamoxifen | 56 | 0.62 (0.37-1.04) | 0.07 | 0.65 (0.37-1.14) | 0.14 | |||||
Cyclin D1 nf >25% | ||||||||||
Control | 84 | 1.00 | 1.00 | |||||||
Tamoxifen | 88 | 0.61 (0.38-0.96) | 0.03 | 0.78 (0.48-1.25) | 0.30 | |||||
Cyclin D1 ni low/intermediate | ||||||||||
Control | 149 | 1.00 | 1.00 | |||||||
Tamoxifen | 120 | 0.59 (0.41-0.85) | 0.004 | 0.72 (0.50-1.06) | 0.10 | |||||
Cyclin D1 ni high | ||||||||||
Control | 18 | 1.00 | 1.00 | |||||||
Tamoxifen | 24 | 0.84 (0.30-2.31) | 0.73 | 0.77 (0.27-2.19) | 0.62 | |||||
Cyclin A2 nf <10% | ||||||||||
Control | 90 | 1.00 | 1.00 | |||||||
Tamoxifen | 69 | 0.51 (0.30-0.86) | 0.01 | 0.72 (0.42-1.25) | 0.25 | |||||
Cyclin A2 nf >10% | ||||||||||
Control | 52 | 1.00 | 1.00 | |||||||
Tamoxifen | 51 | 0.86 (0.50-1.47) | 0.59 | 0.92 (0.53-1.59) | 0.75 | |||||
CCND1 not amplified | ||||||||||
Control | 79 | 1.00 | 1.00 | |||||||
Tamoxifen | 72 | 0.39 (0.23-0.65) | <0.0001 | 0.43 (0.24-0.76) | 0.004 | |||||
CCND1 amplified | ||||||||||
Control | 21 | 1.00 | 1.00 | |||||||
Tamoxifen | 21 | 2.22 (0.94-5.26) | 0.06 | 2.13 (0.89-5.10) | 0.09 |